Trulicity Cost in Rhode Island 2026: Prices, Insurance, Medicaid and Alternatives

What Does Trulicity Actually Cost in Rhode Island?

The cash-pay price for Trulicity at Rhode Island retail pharmacies sits at $931 per month in 2026, matching Eli Lilly's manufacturer list price because no generic exists and pharmacy markup is minimal for this brand. That figure covers a four-pen carton (four weekly doses). Most patients pay far less through insurance or manufacturer assistance, but anyone without coverage faces that full number at the counter.

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1]. The REWIND cardiovascular outcomes trial (N=9,901, median 5.4 years of follow-up) demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death by 12% versus placebo (HR 0.88 to 95% CI 0.79, 0.99, P<0.026) [2]. That cardiovascular benefit is one reason many Rhode Island insurers classify it as a preferred GLP-1 agent rather than a step-therapy fallback.

Prices at specific Rhode Island chains vary by a few dollars based on contracted dispensing fees. GoodRx and similar coupon services typically show cash prices between $880 and $931 at Providence-area CVS, Walgreens, and Rite Aid locations for a four-count, 0.75 mg/0.5 mL pen carton. Patients who bring a GoodRx coupon to a participating pharmacy can sometimes shave $30 to $60 from the sticker price, though the savings card from Lilly almost always beats that for insured patients.

Rhode Island has no state-specific Trulicity pricing legislation as of 2026. Unlike insulin, dulaglutide is not subject to Rhode Island's 2019 insulin cost-sharing cap (RIGL § 27-18-91), so out-of-pocket costs depend entirely on the individual plan's formulary tier and any applicable manufacturer assistance [3].

Does Rhode Island Medicaid (Medicaid/RIte Care) Cover Trulicity?

Rhode Island Medicaid covers dulaglutide with prior authorization (PA) for adults with type 2 diabetes. The PA criteria generally require documented failure of or contraindication to metformin, an HbA1c of 7.5% or higher on current therapy, and confirmation that the prescription is for a type 2 diabetes indication rather than weight loss alone [4].

RIte Care, the managed-care arm of Rhode Island Medicaid administered through Neighborhood Health Plan of Rhode Island and UnitedHealthcare Community Plan, places Trulicity on the preferred drug list when PA is approved. Once PA is granted, patient cost-sharing is typically $3 to $4 per prescription fill under standard Medicaid copay schedules, making it one of the most affordable access pathways for low-income Rhode Island residents. Dual-eligible patients (Medicare and Medicaid) may access it through Medicare Part D with the low-income subsidy (LIS), which caps cost-sharing at $11.20 per month for non-preferred drugs in 2026 under CMS benchmarks [5].

Prescribers submitting a PA request to Rhode Island Medicaid should include current HbA1c lab values, a list of previously tried diabetes medications, and the clinical rationale for GLP-1 therapy. Most PA decisions from Rhode Island Medicaid managed-care organizations are returned within 72 hours for standard requests and 24 hours for urgent requests, consistent with CMS managed-care rules at 42 CFR § 438.210 [6].

Which Commercial Insurance Plans Cover Trulicity in Rhode Island?

Most commercial plans operating in Rhode Island cover Trulicity, though the tier placement determines out-of-pocket cost. Blue Cross Blue Shield of Rhode Island, Tufts Health Plan, and Harvard Pilgrim Health Care are the three largest commercial carriers in the state, and all three include dulaglutide on their formularies for type 2 diabetes with varying PA requirements.

Tier placement matters enormously. A Tier 3 specialty placement can mean $60 to $150 per month after a deductible, while a Tier 2 preferred-brand placement can drop that to $30 to $60. The American Diabetes Association's 2024 Standards of Care state: "GLP-1 receptor agonists with proven cardiovascular benefit should be prescribed for people with type 2 diabetes and established cardiovascular disease regardless of baseline HbA1c or individualized HbA1c target, if not contraindicated" [7]. That guideline language strengthens medical necessity appeals when a plan denies coverage or requires step therapy through a less-studied agent first.

Rhode Island's insurance market follows ACA essential health benefit rules, which require coverage of diabetes medications but do not mandate specific formulary placement. If a plan denies Trulicity and requires trying a GLP-1 agent that lacks the cardiovascular outcomes data dulaglutide has from REWIND, a clinician can file an appeal citing the ADA guideline and REWIND cardiovascular mortality data [2].

Employer-sponsored plans that use national pharmacy benefit managers (PBMs) such as CVS Caremark, Express Scripts, or OptumRx may have different tier placements than individual market plans. Employees should call the number on the back of their insurance card and ask specifically about dulaglutide's formulary tier and whether a Specialty Drug PA is required before the first fill.

How Does the Eli Lilly Savings Card Work in Rhode Island?

The Lilly Trulicity savings card reduces monthly out-of-pocket cost to $25 for eligible commercially insured patients in Rhode Island. The card is available at LillyInsulin.com and participating pharmacies. Eligibility requires commercial or private insurance that covers Trulicity; patients on Medicare, Medicaid, or any other federal or state government-funded program do not qualify [8].

The mechanics are straightforward. The pharmacy runs the patient's insurance first, then applies the Lilly savings card as a secondary payment. Lilly covers the gap between the insurance copay and $25, up to a program maximum (historically $150 per fill). Patients who have a deductible-phase plan may see the card cover a larger share at the start of the year and less once the deductible is met.

Rhode Island pharmacists at major chains are familiar with this card and can process it in a single transaction. Patients should bring both the insurance card and the Lilly savings card to the pharmacy at every fill, because the POS system reprocesses both each time. The savings card does not roll over unused amounts month to month, so there is no benefit to refilling early to bank credits.

For uninsured Rhode Island patients who do not qualify for Medicaid, Lilly offers the Lilly Cares Foundation Patient Assistance Program, which may provide Trulicity at no cost based on income thresholds [8]. Applications require proof of income and a prescriber signature. Processing typically takes two to four weeks, so patients should apply before their current supply runs out.

Is Compounded Dulaglutide Legal in Rhode Island?

Compounded dulaglutide is legally available in Rhode Island through state-licensed 503A compounding pharmacies. A 503A pharmacy operates under state board of pharmacy oversight and compounds medications for individual patient prescriptions, as distinct from 503B outsourcing facilities that produce batch quantities for office use [9].

The FDA does not maintain dulaglutide on its drug shortage list as of early 2026, which is the primary legal basis that has permitted compounded semaglutide and tirzepatide during shortage periods. Dulaglutide compounding therefore occurs under different regulatory logic: 503A pharmacies may compound dulaglutide as an essentially-a-copy preparation only when a prescriber documents a clinical necessity that the commercial product cannot meet, such as an allergy to an inactive ingredient, a required dose not commercially available, or a patient's documented clinical need for a specific formulation [9]. Prescribers in Rhode Island who want to direct a patient to a 503A compounder should document that clinical rationale clearly in the chart.

Rhode Island Board of Pharmacy regulations align with federal 503A standards under the Drug Quality and Security Act (DQSA) of 2013. The board licenses compounding pharmacies and can inspect facilities. Patients should verify that any compounding pharmacy they use holds a current Rhode Island pharmacy license, which can be checked through the Rhode Island Department of Health's online license verification portal [10].

The cost of compounded dulaglutide varies by pharmacy and dose but is substantially below the $931 list price of brand Trulicity. Some Rhode Island-licensed 503A pharmacies quote prices between $150 and $350 per month depending on concentration and vial size. However, compounded products are not FDA-approved, do not carry Lilly's quality-control guarantees, and are not eligible for the Lilly savings card or insurance reimbursement. Prescribers and patients should weigh those trade-offs carefully [9].

Can Rhode Island Patients Get Trulicity Through Telehealth?

Telehealth prescribing of Trulicity is fully permitted in Rhode Island. Rhode Island joined the Interstate Medical Licensure Compact (IMLC), allowing physicians licensed in member states to obtain expedited licensure in Rhode Island, which expands the pool of telehealth providers who can prescribe here [11].

Under Rhode Island telehealth law (RIGL § 5-37.3), a valid prescriber-patient relationship can be established through a synchronous audio-video encounter. A prescriber does not need to conduct an in-person physical exam before prescribing Trulicity via telehealth, provided the visit meets standard-of-care requirements for prescribing a GLP-1 receptor agonist: review of HbA1c, eGFR, history of pancreatitis or MTC, and current medication list [12].

HealthRX telehealth visits for Trulicity follow this protocol. Lab results can be uploaded by the patient or pulled from existing records before the visit. If labs are outdated (generally defined as more than six months old for HbA1c), the provider may order new labs and schedule a follow-up before finalizing the prescription. Rhode Island law does not require a separate in-person visit after a telehealth prescription is issued.

After a telehealth visit, the prescription is sent electronically to any Rhode Island pharmacy the patient chooses, or to a mail-order pharmacy licensed in Rhode Island. Most 90-day mail-order fills via major PBM-affiliated pharmacies are available to Rhode Island residents with valid insurance.

Dulaglutide Dosing and Clinical Profile for Rhode Island Prescribers

Dulaglutide is dosed once weekly by subcutaneous injection. The starting dose is 0.75 mg per week. After at least four weeks, the dose may be increased to 1.5 mg per week. Two additional dose escalation steps are available: 3.0 mg per week (after at least four weeks on 1.5 mg) and 4.5 mg per week (after at least four weeks on 3.0 mg) [1]. The 3.0 mg and 4.5 mg doses were added based on the AWARD-11 trial, which showed dose-dependent HbA1c reductions of 1.87% and 2.02% from baseline at 36 weeks, compared to 1.21% for the 1.5 mg dose [13].

The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies; dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]. Pancreatitis risk, while rare, requires patient counseling and discontinuation if acute pancreatitis is confirmed.

Renal dosing adjustment is not required for dulaglutide, a meaningful clinical advantage over some other antidiabetic agents. A post-hoc analysis of REWIND data published in Diabetes Care showed that dulaglutide reduced the composite renal outcome (new macroalbuminuria, sustained 40% decline in eGFR, or renal replacement therapy) by 15% versus placebo (HR 0.85 to 95% CI 0.77, 0.93) [14]. This nephroprotective signal makes dulaglutide a reasonable choice for Rhode Island patients who have early chronic kidney disease.

The HealthRX Rhode Island GLP-1 Selection Framework (for prescriber reference) applies the following decision sequence for patients presenting with type 2 diabetes in Rhode Island: (1) Confirm cardiovascular or renal comorbidity status using ADA 2024 criteria [7]; (2) Check RI Medicaid or commercial formulary tier before selecting agent; (3) If dulaglutide is preferred by payer, confirm no MTC or MEN 2 contraindication; (4) Start at 0.75 mg weekly and reassess HbA1c at 12 weeks; (5) Escalate dose if HbA1c remains above individualized target; (6) Apply Lilly savings card at first fill for commercially insured patients; (7) Document clinical necessity if directing to a 503A compounder.

Comparing Dulaglutide to Other GLP-1 Options Available in Rhode Island

Rhode Island patients and prescribers have several GLP-1 receptor agonists available. Semaglutide (Ozempic, once-weekly injection; Rybelsus, oral daily) and liraglutide (Victoza, once-daily injection) are the main alternatives for type 2 diabetes. Semaglutide 2.4 mg (Wegovy) and tirzepatide (Mounjaro, Zepbound) are approved for chronic weight management in patients who meet BMI criteria [15].

On efficacy, the SUSTAIN-7 head-to-head trial showed semaglutide 1.0 mg reduced HbA1c by 1.8% versus dulaglutide 1.5 mg at 1.1%, with greater weight loss favoring semaglutide (5.7 kg vs. 2.3 kg) [16]. However, REWIND's long follow-up period (median 5.4 years) and its more broadly representative cardiovascular risk population (only 31.5% had prior cardiovascular disease at baseline) provide distinctive real-world cardiovascular outcomes data that no other GLP-1 trial has replicated for dulaglutide specifically [2].

On cost in Rhode Island, semaglutide (Ozempic) carries a similar list price near $936 per month. Liraglutide (Victoza) is priced around $630 per month list and may be preferred-tier on certain plans. Patients whose plan does not cover Trulicity but does cover Victoza may achieve adequate glycemic control at lower cost, though the cardiovascular outcomes data differ between agents.

Rhode Island Medicaid formulary decisions for GLP-1 agents are updated annually. Prescribers should check the current Preferred Drug List published by the Rhode Island Executive Office of Health and Human Services before selecting an agent purely on formulary grounds, because tier assignments shift between plan years [4].